Late breaking abstracts: Breast cancer
LB35 – LB60
- LB35: Does inbreeding lead to decreased incidence of breast cancer?
- LB36: Cell population dynamics of vitamin D induced reprogramming of malignant breast cancer cells
- LB37: The QUEST Trial: a multi-centre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy
- LB38: Breast cancer phenotype when the “guardian of the genome” fails
- LB39: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells
- LB40: The worries and experiences of the partners of women diagnosed with breast cancer
- LB41: Uptake of National Institute for Health and Clinical Excellence (NICE) approved drugs in Dukes C colorectal cancer and early breast cancer patients
- LB42: Clinico-pathologic and molecular predictors of axillary lymph node status in early stage breast cancer: a mathematical logistic regression predictive model
- LB43: Growth fraction assessment using Ki-67/Mib1 labelling index: a predictor of response to adjuvant therapy in breast cancer patients
- LB44: Sleep duration and breast cancer risk: a meta-analysis
- LB45: Identification of potential therapeutic targets in HER2 amplified breast carcinomas by integrative molecular profiling
- LB46: BRCA1: Notch another target?
- LB47: A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015)
- LB48: Identification of molecular pathways regulated by gene copy number aberrations in breast cancer
- LB49: Neo-tAnGo: a neoadjuvant randomised phase III trial of epirubicin / cyclophosphamide (EC) and paclitaxel (T) ± gemcitabine (G) in the treatment of women with high-risk early breast cancer (EBC)
- LB50: Breast cancer risk among foreign-born women in Sweden: a focus on British women and the effect of age at immigration and duration of residence
- LB51: Lifestyle intervention reduces mild/moderate depression and improves quality of life in breast cancer patients
- LB52: FGF-2 expression is altered in myoepithelial cells from cancer-containing breasts
- LB53: Dissociation between oestrogen receptor alpha (ER) expression and stem cell activity in human breast cancer provides a novel mechanism of endocrine resistance
- LB54: The identification of transcriptional targets of TBX2 and their role in breast cancer proliferation
- LB55: Oestrogen receptor interactions with the coactivator AIB1 in development of resistance to aromatase inhibitor treatment for breast cancer
- LB56: Identifying cell growth control pathways repressed by the oncogene TBX2 in breast cancer cells
- LB57: The developmental protein HOXC11 cooperates with SRC-1 in breast cancer: an adaptive response to endocrine therapy
- LB58: The identification of pathways responsible for driving the proliferation of basal-like breast cancers
- LB59: An integrative analysis of genome copy number, whole genome expression and cancer gene methylation status in breast cancer cell lines of basal-like phenotype
- LB60: Long-term anastrozole versus tamoxifen treatment effects: LATTE Study
